A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Narita, Naofumi ^a   Yuasa, Takeshi ^a   Tsuchiya, Norihiko ^a   Kumazawa, Teruaki ^a   Narita, Shintaro ^a   Inoue, Takamitsu ^a   Ma, Zhiyong ^a   Saito, Mitsuru ^a   Horikawa, Yohei ^a   Satoh, Shigeru ^a   Ogawa, Osamu ^b   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; BONE METABOLISM; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTEIN FUNCTION; RISK ASSESSMENT; BIOLOGICAL MODEL; CASE CONTROL STUDY; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR; RISK;

AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; ODDS RATIO; OSTEOPROTEGERIN; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RISK;

EID: 51249088776     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-224     Document Type: Article

References (27)

1. Roodman GD Mechanisms of bone metastasis N Engl J Med 2004, 350:1655-64. 10.1056/NEJMra030831 15084698
2. Tsuchiya N Wang L Suzuki H Segawa T Fukuda H Narita S Shimbo M Kamoto T Mitsumori K Ichikawa T Ogawa O Nakamura A Habuchi T Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer J Clin Oncol 2006, 24:1982-9. 10.1200/JCO.2005.02.9439 16648498
3. Wittrant Y Theoleyre S Chipoy C Padrines M Blanchard F Heymann D Redini F RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis Biochim Biophys Acta 2004, 1704:49-57. 15363860
4. Hofbauer LC Schoppet M Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases JAMA 2004, 292:490-5. 10.1001/jama.292.4.490 15280347
5. Corey E Brown LG Kiefer JA Quinn JE Pitts TE Blair JM Vessella RL Osteoprotegerin in prostate cancer bone metastasis Cancer Res 2005, 65:1710-8. 10.1158/0008-5472.CAN-04-2033 15753366
6. Zhang J Dai J Qi Y Lin DL Smith P Strayhorn C Mizokami A Fu Z Westman J Keller ET Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone J Clin Invest 2001, 107:1235-44. 209296 11375413 10.1172/JCI11685
7. Morinaga T Nakagawa N Yasuda H Tsuda E Higashio K Cloning and characterization of the gene encoding human osteoprotegerin/ osteoclastogenesis-inhibitory factor Eur J Biochem 1998, 254:685-91. 10.1046/j.1432-1327.1998.2540685.x 9688283
8. Langdahl BL Carstens M Stenkjaer L Eriksen EF Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures J Bone Miner Res 2002, 17:1245-55. 10.1359/jbmr.2002.17.7.1245 12096838
9. Yamada Y Ando F Niino N Shimokata H Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men Mol Genet Metab 2003, 80:344-9. 10.1016/S1096-7192(03)00125-2 14680982
10. Ueland T Bollerslev J Wilson SG Dick IM Islam FM Mullin BH Devine A Prince RL No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women Bone 2007, 40:175-81. 10.1016/j.bone.2006.06.022 16949901
11. Vidal C Brincat M Xuereb R Anastasi A TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta Maturitas 2006, 53:386-95. 10.1016/j.maturitas.2005.11.003 16343827
12. Arko B Prezelj J Komel R Kocijancic A Hudler P Marc J Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis J Clin Endocrinol Metab 2002, 87:4080-4. 10.1210/jc.2002-020124 12213850
13. Ohmori H Makita Y Funamizu M Hirooka K Hosoi T Orimo H Suzuki T Ikari K Nakajima T Inoue I Hata A Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis J Hum Genet 2002, 47:400-6. 10.1007/s100380200058 12181640
14. International Union against Cancer From Prostate TNM classification of malignant tumors New York: Wiley-Liss Sobin LH, Wittekind C 6 2002:184-7.
15. Gleason DF From Histological grading and clinical staging of prostate carcinoma Urologic pathology New York: Wiley-Liss Tannenbaum M 1977:171-97.
16. Fleming ID Ed Prostate Cancer AJCC Cancer Staging Manual New York: Springer 6 2002:309-316.
17. Paget S The distribution of secondary growths in cancer of the breast Lancet 1889, 1:571-573. 10.1016/S0140-6736(00)49915-0
18. Ohmori R Momiyama Y Taniguchi H Tanaka N Kato R Nakamura H Ohsuzu F Nagano M Egashira T Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men Atherosclerosis 2006, 187:215-7. 10.1016/j.atherosclerosis.2006.03.026 16678184
19. Brandstrom H Stiger F Lind L Kahan T Melhus H Kindmark A A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function Biochem Biophys Res Commun 2002, 293:13-7. 10.1016/S0006-291X(02)00137-7 12054556
20. Soufi M Schoppet M Sattler AM Herzum M Maisch B Hofbauer LC Schaefer JR Osteoprotegerin gene polymorphisms in men with coronary artery disease J Clin Endocrinol Metab 2004, 89:3764-8. 10.1210/jc.2003-032054 15292302
21. Brown JM Vessella RL Kostenuik PJ Dunstan CR Lange PH Corey E Serum osteoprotegerin levels are increased in patients with advanced prostate cancer Clin Cancer Res 2001, 7:2977-83. 11595685
22. Jung K Lein M Stephan C Von Hosslin K Semjonow A Sinha P Loening SA Schnorr D Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications Int J Cancer 2004, 111:783-91. 10.1002/ijc.20314 15252851
23. Eaton CL Wells JM Holen I Croucher PI Hamdy FC Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer Prostate 2004, 59:304-10. 10.1002/pros.20016 15042606
24. Kudlacek S Schneider B Woloszczuk W Pietschmann P Willvonseder R Austrian Group on Normative Values of Bone Metabolism Serum levels of osteoprotegerin increase with age in healthy adult population Bone 2003, 32:681-686. 10.1016/S8756-3282(03)00090-5 12810175
25. Indridason OS Franzson L Sigurdsson G Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover Osteoporos Int 2005, 16:417-423. 10.1007/s00198-004-1699-x 15776220
26. Lipton A Ali SM Leitzel K Chinchilli V Witters L Engle L Holloway D Bekker P Dunstan CR Serum osteoprotegerin levels in healthy controls and cancer patients Clin Cancer Res 2002, 8;2306-10. 12114435
27. Cao J Venton L Sakata T Halloran BP Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice J Bone Miner Res 2003, 18:270-7. 10.1359/jbmr.2003.18.2.270 12568404